Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104611 · ClinicalTrials.gov registry record · Phase 3
Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder
A Phase 3 study, sponsored by Neuronetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 286
- Enrollment target
NCT00104611 is a Phase 3 study that has completed, run by Neuronetics. The registered enrollment target is 286 participants.
The verdict
NCT00104611, a Phase 3 study, has completed, sponsored by Neuronetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 286 participants
- Enrollment target
Study Summary
This trial will test the safety and efficacy of a rTMS device for the treatment of major depressive disorder (MDD). It is hypothesized that rTMS will have an antidepressant effect. It is a 10-week, randomized, sham-controlled, multicenter trial in outpatients recruited in both academic and private research centers. It is comprised of three major phases: pre-study screening, acute treatment, and post-treatment taper. Eligible patients will be randomized to one of two rTMS treatment groups. One group will receive active rTMS treatment and one will receive an inactive, or sham, treatment. Each treatment takes about 45 minutes and is done on an outpatient basis. All trial related medical care is provided at no cost to the participant.
Interventions
- DEVICE Repetitive Transcranial Magnetic Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104611
The ClinicalTrials.gov registry entry for NCT00104611 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuronetics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Repetitive Transcranial Magnetic Stimulation is the first listed.
NCT00104611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00104611 about?
NCT00104611 is a clinical study titled "Study of a Repetitive Transcranial Magnetic Stimulation (rTMS) Device for the Treatment of Major Depressive Disorder". This trial will test the safety and efficacy of a rTMS device for the treatment of major depressive disorder (MDD). It is hypothesized that rTMS will have an antidepressant effect. It is a 10-week, randomized, sham-controlled, multicenter trial in outpatients recruited in both academic and private ...
What is the current status of trial NCT00104611?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 286 participants. The study started on 2004-01. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00104611?
The interventions under investigation include: Repetitive Transcranial Magnetic Stimulation (DEVICE).
Who is sponsoring clinical trial NCT00104611?
This trial is sponsored by Neuronetics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.